Compare WWW & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WWW | NVAX |
|---|---|---|
| Founded | 1883 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2001 | 1996 |
| Metric | WWW | NVAX |
|---|---|---|
| Price | $20.06 | $11.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $23.25 | $11.33 |
| AVG Volume (30 Days) | 1.1M | ★ 3.9M |
| Earning Date | 05-25-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | 0.76 | ★ 2.58 |
| Revenue | ★ $1,755,000,000.00 | $1,123,479,000.00 |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $4.83 | N/A |
| P/E Ratio | $26.47 | ★ $4.37 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $9.58 | $5.01 |
| 52 Week High | $32.80 | $11.85 |
| Indicator | WWW | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 64.47 | 74.43 |
| Support Level | $16.82 | $6.34 |
| Resistance Level | $20.26 | N/A |
| Average True Range (ATR) | 0.78 | 0.63 |
| MACD | 0.14 | 0.16 |
| Stochastic Oscillator | 70.90 | 85.13 |
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.